Equities research analysts predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report earnings of ($0.14) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.06). Ironwood Pharmaceuticals also reported earnings of ($0.14) per share in the same quarter last year. The firm is expected to issue its next quarterly earnings results on Thursday, February 21st.
On average, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($0.94) per share for the current year, with EPS estimates ranging from ($1.09) to ($0.72). For the next year, analysts anticipate that the business will post earnings of $0.27 per share, with EPS estimates ranging from ($0.12) to $0.74. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.24). The company had revenue of $68.69 million during the quarter, compared to analysts’ expectations of $93.48 million. During the same period last year, the company earned ($0.18) earnings per share. Ironwood Pharmaceuticals’s quarterly revenue was down 20.9% on a year-over-year basis.
In other news, insider Mark G. Currie sold 116,651 shares of Ironwood Pharmaceuticals stock in a transaction on Friday, October 5th. The stock was sold at an average price of $17.53, for a total value of $2,044,892.03. Following the completion of the sale, the insider now directly owns 70,680 shares of the company’s stock, valued at approximately $1,239,020.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark G. Currie sold 130,000 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $18.45, for a total value of $2,398,500.00. Following the completion of the sale, the insider now directly owns 791,666 shares of the company’s stock, valued at $14,606,237.70. The disclosure for this sale can be found here. Insiders sold a total of 248,339 shares of company stock valued at $4,475,466 over the last three months. Insiders own 7.63% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG boosted its position in shares of Ironwood Pharmaceuticals by 627.0% in the 1st quarter. UBS Group AG now owns 154,957 shares of the biotechnology company’s stock worth $2,392,000 after purchasing an additional 133,641 shares during the last quarter. A.R.T. Advisors LLC bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth $208,000. LPL Financial LLC boosted its position in shares of Ironwood Pharmaceuticals by 16.3% in the 1st quarter. LPL Financial LLC now owns 21,160 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 2,959 shares during the last quarter. Guggenheim Capital LLC boosted its position in shares of Ironwood Pharmaceuticals by 2.4% in the 1st quarter. Guggenheim Capital LLC now owns 188,974 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 4,372 shares during the last quarter. Finally, Xact Kapitalforvaltning AB boosted its position in shares of Ironwood Pharmaceuticals by 54.6% in the 1st quarter. Xact Kapitalforvaltning AB now owns 22,655 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 8,000 shares during the last quarter. 97.29% of the stock is owned by institutional investors.
IRWD stock traded down $0.20 during midday trading on Monday, reaching $11.88. 1,677,504 shares of the company’s stock traded hands, compared to its average volume of 1,784,796. Ironwood Pharmaceuticals has a 1-year low of $11.62 and a 1-year high of $21.20. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -12.77 and a beta of 1.33.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Further Reading: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.